CV Therapeutics Ranexa Benefit Over Norvasc Will Be Focus Of Additional Phase III Trial

Refractory angina trial designed under a special protocol assessment with FDA will begin in the third quarter. The company predicts a "broad restricted label" based on the study, which follows recommendations made by FDA's Cardio-Renal Drugs Advisory Committee.